Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term

Eli Lilly's biotech strategy calls for the creation of a pipeline that will yield one new biotechnology-based drug launch each year beginning in 2011, the company announced

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet